TW202114676A - 治療癌症之方法 - Google Patents

治療癌症之方法 Download PDF

Info

Publication number
TW202114676A
TW202114676A TW109127558A TW109127558A TW202114676A TW 202114676 A TW202114676 A TW 202114676A TW 109127558 A TW109127558 A TW 109127558A TW 109127558 A TW109127558 A TW 109127558A TW 202114676 A TW202114676 A TW 202114676A
Authority
TW
Taiwan
Prior art keywords
patient
entratinib
administration
cancer
grade
Prior art date
Application number
TW109127558A
Other languages
English (en)
Chinese (zh)
Inventor
羅倫特 喬治亞納 曼尼瑟斯
艾德納 喬 曼諾瓦
普拉提克 S 莫爾坦尼
蘇珊 黛安 恩格
阿寇斯塔 賽吉歐 瑞內 雷
Original Assignee
瑞士商F 賀夫曼 賀許公司
美商伊格尼塔公司
美商總體科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商F 賀夫曼 賀許公司, 美商伊格尼塔公司, 美商總體科技公司 filed Critical 瑞士商F 賀夫曼 賀許公司
Publication of TW202114676A publication Critical patent/TW202114676A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW109127558A 2019-08-14 2020-08-13 治療癌症之方法 TW202114676A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962886948P 2019-08-14 2019-08-14
US62/886,948 2019-08-14

Publications (1)

Publication Number Publication Date
TW202114676A true TW202114676A (zh) 2021-04-16

Family

ID=72266851

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109127558A TW202114676A (zh) 2019-08-14 2020-08-13 治療癌症之方法

Country Status (6)

Country Link
US (1) US20220257592A1 (cg-RX-API-DMAC7.html)
EP (1) EP4013404A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022545387A (cg-RX-API-DMAC7.html)
CN (1) CN114222576A (cg-RX-API-DMAC7.html)
TW (1) TW202114676A (cg-RX-API-DMAC7.html)
WO (1) WO2021030619A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230454A1 (en) * 2022-05-24 2023-11-30 Icahn School Of Medicine At Mount Sinai Neurotrophic tyrosine receptor kinase inhibitors as therapeutics for liver disease
CN121371180A (zh) * 2025-12-18 2026-01-23 中南大学湘雅二医院 一种用于治疗存在ntrk和/或ros1突变的恶性肿瘤脑膜转移的药物、应用及药物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
KR20230170136A (ko) * 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법

Also Published As

Publication number Publication date
WO2021030619A1 (en) 2021-02-18
US20220257592A1 (en) 2022-08-18
EP4013404A1 (en) 2022-06-22
CN114222576A (zh) 2022-03-22
JP2022545387A (ja) 2022-10-27

Similar Documents

Publication Publication Date Title
AU2016370846B2 (en) Combinations for the treatment of cancer
TWI785074B (zh) 醫藥組合物及劑型
CN111225662B (zh) 药物组合物和剂型
US20170356918A1 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
TW201821078A (zh) 治療癌症之方法
US20220257592A1 (en) Methods of treating cancer
CN116217657A (zh) 蛋白质界面
HK40069081A (en) Methods of treating cancer
BR122025029354A2 (pt) Método para preparar composição farmacêutica
HK40016507A (en) Pharmaceutical compositions comprising entrectinib
HK1261529A1 (en) Combinations for the treatment of cancer